The CIS market for insulin and insulin products is expected to reach USD 3,008.5 million by 2020 growing at a CAGR of 15.0%. The presence of an extensive pipeline portfolio of products exhibiting higher efficacies and their subsequent commercialization over the next six years is expected to serve this market as a high impact rendering driver. The introduction of government initiatives aimed at improving the affordability of insulin via price reduction, such as the collaboration between the government of Ukraine and Indar to reduce the price of insulin by 20% in 2013 is expected to have positive influence on demand. Some of the other drivers of this market include increasing attempts made by manufacturers to capitalize on the untapped opportunities by opening new manufacturing units to improve the supply of insulin and growing incidence rates of type II diabetes are some of the factors expected to fuel future market growth.
Browse the report:http://www.orbisresearch.com/reports/index/cis-insulin-market-rapid-acting-short-acting-pre-mixed-long-acting-type-i-and-ii-diabetes-analogs-recombinant-insulin-analysis-and-segment-forecasts-to-2020
Further key findings from the study suggest:
Regionally, Russia occupied the largest share of the market, accounting for 69.2% of the revenue. Its large share is majorly attributed by the subsidies that Russian government provides to make insulin more affordable for patients.
Ukraine is expected to register the fastest CAGR of 15.6% during the forecast period due to the presence of high untapped opportunities and encouraging government initiatives.
Request a sample of the report:http://www.orbisresearch.com/contacts/request-sample/61474
In addition, Poland is expected to grow at a lucrative rate during the forecast period majorly owing to the presence of high diabetes prevalence coupled with increasing healthcare expenditures.
Long acting insulin accounted for the largest share of the market, at over 39.0% in 2013, owing to the higher preference given to long acting insulin therapy for diabetes which results in lesser episodes of low blood sugar. It is also expected that this product segment will grow at the fastest CAGR of over 18.0% during the next six years.
Buy the report@http://www.orbisresearch.com/contact/purchase/61474
Application of insulin for control of type II diabetes occupied for over 90.0% of the market owing to the presence of larger portfolio of products catering to this segment and a relatively larger prevalence base.
Analogs accounted for over 80.0% of the revenue owing to their relatively higher prices and better efficacy levels. In addition, this segment is expected to exhibit the fastest CAGR during the forecast period on account of the introduction of technologically advanced products such as ultra-long and ultra-fast acting analogs.
Major points From table Of Contents:
Chapter One: Executive Summary
Chapter Two: CIS Insulin Industry Outlook
Chpter Three: CIS Insulin Product Outlook, Volume (number of units) and Value (USD Million) Estimates andForecasts, 2012 – 2020
Chapter Four: CIS Insulin Segment (on the basis of source) Outlook, Volume (number of units) and Value (USDMillion) Estimates and Forecasts, 2012 – 2020
Chapter Five: CIS Insulin Application Outlook(USD Million) Estimates and Forecasts, 2012 – 2020
Chapter Six: Insulin egional Outlook, Volume (number of units) and Value (USD Million) Estimates and Forecasts, 2012 – 2020
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019